Protocol › Age criteria · Last reviewed 2026-05-16

Age criteria and Tanner stages

Summary

The original Dutch Protocol set thresholds at Tanner stage 2 (about 11–12 years) for puberty suppression, 16 for cross-sex hormones and 18 for surgery. The Endocrine Society guideline of 2017 maintained these benchmarks but allowed hormones to begin before age 16 in selected cases, with documented consent of the patient and parents.

1. Tanner stages

The Tanner stages (1962) describe the progression of sexual maturation. The Dutch Protocol uses the Tanner stage as a criterion for starting GnRH agonists:

TannerFeature girlsFeature boysAge (mean)
1PrepubertalPrepubertal< 10–11
2Beginning breast development (thelarche)Testicular volume 4 ml+10–12
3Further breast development, pubic hairVoice change begins12–13
4Breast development almost completeFacial hair13–15
5AdultAdult15+

2. Original age thresholds

InterventionMinimum criterionSource
GnRH agonistTanner 2 (~12 years)Delemarre 2006
Cross-sex hormones16 yearsDelemarre 2006
Surgery18 yearsDelemarre 2006

3. Adjustments under Endocrine Society 2017

The Endocrine Society in its revised guideline (2017) suggested that there may be "compelling reasons" to start cross-sex hormones before the age of 16 in some adolescents (as summarised in WPATH SOC-8: source).1 This relaxation was criticised by various later authors as a deviation from the original Dutch design; see WPATH SOC and the Dutch Protocol.

4. Application in later international practice

In the UK, the 2011 early intervention study recruited patients aged 12-15 with inclusion criteria in line with the original Dutch protocol; the Cass Review calls it the only formal attempt to replicate the Dutch approach.2 The Cass Review (2024) writes that the approach was later extended to a broader group of adolescents who would not have met the inclusion criteria of the original Dutch study (source). Finland (COHERE 2020) and the UK have restricted medical treatment of minors since 2020; the Cass Review notes that the Finnish and Swedish guidelines recommend medical treatment, in the absence of evidence, only within a research framework (source).

Critical note

The age thresholds were set in a protocol whose evidence base is limited. The York systematic review for the Cass Review (2024) found limited or inconsistent evidence on the effects of puberty suppression (source), and SBU (2022) found the evidence insufficient to assess the effects of hormone treatment in adolescents (source).3

See also

Footnotes

  1. Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons. J Clin Endocrinol Metab. 2017;102(11):3869–903.
  2. Cass H. Independent review of gender identity services for children and young people: final report. NHS England; April 2024.
  3. SBU. Hormone treatment of children and adolescents with gender dysphoria. Stockholm; 2022. Report 342.